OBJECTIVE: To deliver rapid isoniazid (INH) and rifampicin (RMP) drug susceptibility testing (DST) close to the patient, we designed a decentralisation process for the microscopic observation drug susceptibility (MODS) assay in Peru and evaluated its reliability. METHODS: After 2 weeks of training, laboratory staff processed ≥ 120 consecutive sputum samples each in three regional laboratories. Samples were processed in parallel with MODS testing at an expert laboratory. Blinded paired results were independently analysed by the Instituto Nacional de Salud (INS) according to pre-determined criteria: concordance for culture, DST against INH and RMP and diagnosis of multidrug-resistant tuberculosis (MDR-TB) ≥ 95%, McNemar's P > 0.05, kappa index (κ) ≥ 0.75 and contamination 1-4%. Sensitivity and specificity for MDR-TB were calculated. RESULTS: The accreditation process for Callao (126 samples, 79.4% smear-positive), Lima Sur (n = 130, 84%) and Arequipa (n = 126, 80%) took respectively 94, 97 and 173 days. Pre-determined criteria in all regional laboratories were above expected values. The sensitivity and specificity for detecting MDR-TB in regional laboratories were >95%, except for sensitivity in Lima Sur, which was 91.7%. Contamination was 1.0-2.3%. Mean delay to positive MODS results was 9.9-12.9 days. CONCLUSION: Technology transfer of MODS was reliable, effective and fast, enabling the INS to accredit regional laboratories swiftly.
OBJECTIVE: To deliver rapid isoniazid (INH) and rifampicin (RMP) drug susceptibility testing (DST) close to the patient, we designed a decentralisation process for the microscopic observation drug susceptibility (MODS) assay in Peru and evaluated its reliability. METHODS: After 2 weeks of training, laboratory staff processed ≥ 120 consecutive sputum samples each in three regional laboratories. Samples were processed in parallel with MODS testing at an expert laboratory. Blinded paired results were independently analysed by the Instituto Nacional de Salud (INS) according to pre-determined criteria: concordance for culture, DST against INH and RMP and diagnosis of multidrug-resistant tuberculosis (MDR-TB) ≥ 95%, McNemar's P > 0.05, kappa index (κ) ≥ 0.75 and contamination 1-4%. Sensitivity and specificity for MDR-TB were calculated. RESULTS: The accreditation process for Callao (126 samples, 79.4% smear-positive), Lima Sur (n = 130, 84%) and Arequipa (n = 126, 80%) took respectively 94, 97 and 173 days. Pre-determined criteria in all regional laboratories were above expected values. The sensitivity and specificity for detecting MDR-TB in regional laboratories were >95%, except for sensitivity in Lima Sur, which was 91.7%. Contamination was 1.0-2.3%. Mean delay to positive MODS results was 9.9-12.9 days. CONCLUSION: Technology transfer of MODS was reliable, effective and fast, enabling the INS to accredit regional laboratories swiftly.
Authors: David A J Moore; Daniel Mendoza; Robert H Gilman; Carlton A W Evans; María-Graciela Hollm Delgado; Jose Guerra; Luz Caviedes; Daniel Vargas; Eduardo Ticona; Jaime Ortiz; Giselle Soto; Jose Serpa Journal: J Clin Microbiol Date: 2004-10 Impact factor: 5.948
Authors: Mayra Arias; Fernanda C Q Mello; Ada Pavón; Anna Grazia Marsico; Carlos Alvarado-Gálvez; Senia Rosales; Carlos Leonardo Carvalho Pessôa; Melly Pérez; Monica K Andrade; Afranio L Kritski; Leila S Fonseca; Richard E Chaisson; Michael E Kimerling; Susan E Dorman Journal: Clin Infect Dis Date: 2007-01-22 Impact factor: 9.079
Authors: David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland Journal: N Engl J Med Date: 2006-10-12 Impact factor: 91.245
Authors: J Coronel; M Roper; S Mitchell; E Castillo; N Gamarra; F Drobniewski; G Luna; A Mendoza; D A J Moore Journal: Int J Tuberc Lung Dis Date: 2010-11 Impact factor: 2.373
Authors: L Caviedes; T S Lee; R H Gilman; P Sheen; E Spellman; E H Lee; D E Berg; S Montenegro-James Journal: J Clin Microbiol Date: 2000-03 Impact factor: 5.948
Authors: Marco Tovar; Mark J Siedner; Robert H Gilman; Carlos Santillan; Luz Caviedes; Teresa Valencia; Oswaldo Jave; A Rod Escombe; David A J Moore; Carlton A Evans Journal: Clin Infect Dis Date: 2008-03-15 Impact factor: 9.079
Authors: N Quispe; L Asencios; C Obregon; G E Velásquez; C D Mitnick; M Lindeborg; H Jave; L Solari Journal: Int J Tuberc Lung Dis Date: 2020-02-01 Impact factor: 2.373
Authors: Hila Elinav; Henry D Kalter; Luz Caviedes; Lawrence H Moulton; Eshetu Lemma; Andrea Rajs; Colin Block; Shlomo Maayan Journal: Am J Trop Med Hyg Date: 2012-04 Impact factor: 2.345
Authors: A Mendoza-Ticona; E Alarcón; V Alarcón; K Bissell; E Castillo; I Sabogal; J Mora; D Moore; A D Harries Journal: Public Health Action Date: 2012-12-21
Authors: Louis Grandjean; Tomotada Iwamoto; Anna Lithgow; Robert H Gilman; Kentaro Arikawa; Noriko Nakanishi; Laura Martin; Edith Castillo; Valentina Alarcon; Jorge Coronel; Walter Solano; Minoo Aminian; Claudia Guezala; Nalin Rastogi; David Couvin; Patricia Sheen; Mirko Zimic; David A J Moore Journal: PLoS One Date: 2015-05-18 Impact factor: 3.240
Authors: Alice L den Hertog; Sandra Menting; Ernst T Smienk; Jim Werngren; Sven Hoffner; Richard M Anthony Journal: BMC Infect Dis Date: 2014-07-10 Impact factor: 3.090